H.R. 5160: Stem Cell Therapeutic and Research Reauthorization Act of 2025 is likely a bill aimed at reauthorizing and potentially expanding funding and support for stem cell research and therapeutic applications. This could include provisions for the collection, storage, and distribution of stem cells for medical research and treatment, as well as ensuring ongoing government support for advancements in this field.
Media coverage has highlighted the potential of H.R. 5160 to advance medical research and treatment options for various diseases and conditions, emphasizing the importance of continued federal support for stem cell therapies. Advocates argue that the bill could lead to breakthroughs in regenerative medicine, offering hope to patients with conditions like spinal cord injuries, diabetes, and heart disease.
Critics of H.R. 5160 have raised concerns about ethical implications surrounding stem cell research, particularly regarding the use of embryonic stem cells. Some media outlets have reported on the divisive nature of the bill, suggesting that it may reignite debates over funding priorities and moral considerations associated with stem cell research.
The sponsorship of H.R. 5160 by Christopher Smith raises potential conflicts of interest due to significant financial contributions from the health professionals sector, totaling $120 million. This sector is directly related to the subject matter of the bill, which focuses on stem cell therapeutic research and reauthorization. The alignment of the sponsor's top donor industry with the bill's focus suggests a potential bias towards legislation that may favor the interests of these donors. Furthermore, while the total donations from the health professionals sector are substantial, the absence of PAC contributions indicates that these funds come from individual donors, which may complicate the perception of influence. Voters should be aware that the financial interests of health professionals could shape the legislative agenda in ways that may not align with broader public health interests.
These industries are both affected by this bill and among the sponsor's top donors.
| Industry | Match Type | Related Subject | Donations |
|---|---|---|---|
| Health Professionals (H01) | Sector | Health | $120,000,000 |
| Total from overlapping industries | $120,000,000 | ||
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| DIRSHU INTERNATIONAL | MERKAVA STRATEGIES CORPORATION | $100,000 |
| CEO WORKS | SAUNDERS GLOBAL DIPLOMACY | $45,000 |
| KAZI IG | SAUNDERS GLOBAL DIPLOMACY | $15,000 |
| KEY LARGO WASTEWATER TREATMENT DISTRICT | HICKS-RICHARDSON ASSOCIATES | $10,000 |
| WATERFRONT GLOBAL | BBT STRATEGIES LLC | $5,200 |
| DIGITALEUROPE | VIVID STRATEGIES LLC | undisclosed |
| INTERNATIONAL CHRISTIAN CHAMBER OF COMMERCE | MERKAVA STRATEGIES CORPORATION | undisclosed |
| DR. STEPHEN SOLOWAY | MERKAVA STRATEGIES CORPORATION | undisclosed |
| ONE ISRAEL FUND | MERKAVA STRATEGIES CORPORATION | undisclosed |
| HEMOGLOBIN OXYGEN THERAPEUTICS | MERKAVA STRATEGIES CORPORATION | undisclosed |
| ATAOLLAH AMINPOUR | MERKAVA STRATEGIES CORPORATION | undisclosed |
| HERSEL NEMAN | MERKAVA STRATEGIES CORPORATION | undisclosed |
| MORAD BEN NEMAN | MERKAVA STRATEGIES CORPORATION | undisclosed |
| MARK SCOTT | MERKAVA STRATEGIES CORPORATION | undisclosed |
| BORIS MINTS | MERKAVA STRATEGIES CORPORATION | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
Top industries funding Christopher Smith, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
